TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06657222: First in Human Study of TUB-030 in Patients With Advanced Solid Tumors

Sponsor: Gilead Sciences · Phase: PHASE1/PHASE2 · Area: ONCOLOGY · Target Enrollment: 250 pts

Competing Trials Overlap

13 Active Trials

Excess Burn Exposure

$2,748,900

Rescue Site Savings

+$1,806,420

Unlock Full NCT06657222 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06657222 Rescue Dossier →